Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Outpatient Department, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
PLoS One. 2023 Mar 16;18(3):e0282419. doi: 10.1371/journal.pone.0282419. eCollection 2023.
Chronic pain affects more than 30% of the general population. The 9-item Central Sensitization Inventory (CSI-9) is a shortened version of the CSI-25, which is a patient-reported instrument used to screen people at risk of central sensitization (CS). The aim of this study was to cross-culturally adapt and validate a Chinese version of the CSI-9. The Chinese CSI-9 was generated by translation of the original English version, back-translation, cultural adaptation, and revision using the Delphi method. The Chinese CSI-9 was administered to 235 patients with chronic pain and 55 healthy controls. Structural validity (confirmatory factor analysis), construct validity (correlations with other scales), test-retest reliability (intraclass correlation coefficient, ICC), and internal consistency (Cronbach's α) were evaluated. Confirmatory factor analysis was performed using one factor. The Chinese CSI-9 score was positively correlated with the Pain Catastrophic Scale (PCS) total score (r = 0.463), PCS subscale scores (r = 0.347-0.463), Brief Pain Inventory (BPI) mean item score (r = 0.524), BPI total score (r = 0.773), and the number of painful sites (r = 0.451). The Chinese CSI-9 had excellent test-retest reliability (ICC = 0.958) and excellent internal consistency (Cronbach's α = 0.902 in the overall sample and 0.828 in the chronic pain population). The optimal cut-off value for the Chinese CSI-9 was 18 points. The Chinese CSI-9 had excellent test-retest reliability and satisfactory structural validity and construct validity. The CSI-9 could potentially be utilized in China as a self-report questionnaire in both clinical practice and research settings.
慢性疼痛影响超过 30%的一般人群。9 项中枢敏化量表(CSI-9)是 CSI-25 的缩短版,CSI-25 是一种用于筛查有中枢敏化(CS)风险的患者的患者报告工具。本研究的目的是跨文化适应和验证 CSI-9 的中文版本。中文 CSI-9 通过翻译原始英文版、回译、文化适应和使用 Delphi 方法修订生成。中文 CSI-9 用于 235 名慢性疼痛患者和 55 名健康对照者。评估结构效度(验证性因子分析)、结构效度(与其他量表的相关性)、重测信度(组内相关系数,ICC)和内部一致性(Cronbach's α)。使用单因素进行验证性因子分析。中文 CSI-9 评分与疼痛灾难量表(PCS)总分(r = 0.463)、PCS 分量表评分(r = 0.347-0.463)、简明疼痛量表(BPI)平均项目评分(r = 0.524)、BPI 总分(r = 0.773)和疼痛部位数量(r = 0.451)呈正相关。中文 CSI-9 具有极好的重测信度(ICC = 0.958)和极好的内部一致性(总体样本的 Cronbach's α = 0.902,慢性疼痛人群的 Cronbach's α = 0.828)。中文 CSI-9 的最佳截断值为 18 分。中文 CSI-9 具有极好的重测信度和令人满意的结构效度和结构效度。CSI-9 可能在中国作为一种自我报告问卷,用于临床实践和研究环境。